Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10785407 | 0.90 | LMNA (0.58) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL11867756 | 0.84 | LMNA (0.44) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL8737261 | 0.84 | CYP2C19 (0.71) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL23457202 | 0.84 | LMNA (0.54) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL3308217 | 0.82 | CYP2C19 (0.69) | LMNAHSD17B10ALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL9902119 | 0.82 | ALDH1A1 (0.49) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL6127341 | 0.82 | ALDH1A1 (0.49) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL7580361 | 0.80 | L3MBTL1 (0.59) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL10556985 | 0.80 | CYP2C19 (0.47) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL15658358 | 0.80 | ALDH1A1 (0.47) | L3MBTL1TDP1LMNAHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103459467-B | Polybenzoxazole resin and precursor thereof | MITSUBISHI GAS CHEMICAL CO.,INC. (JP) | 2016-04-06 | — | — | CN | claimed |
| CN-103459467-B | Polybenzoxazole resin and precursor thereof | MITSUBISHI GAS CHEMICAL CO.,INC. (JP) | 2016-04-06 | — | — | CN | disclosed |
| CN-103459467-A | Polybenzoxazole resin and precursor thereof | MITSUBISHI GAS CHEMICAL CO | 2013-12-18 | — | — | CN | disclosed |
| CN-100355714-C | Arylpiperazines having 5-hydroxyl-typtamine activity | LILLY CO ELI (US) | 2007-12-19 | — | — | CN | disclosed |
| US-7309702-B2 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; Alzheimer's disease | AVERA PHARMACEUTICALS, INC. (US) | 2007-12-18 | — | — | US | disclosed |
| CN-1743302-A | Arylpiperazines having 5-hydroxyl-typtamine activity | LILLY CO ELI (US) | 2006-03-08 | — | — | CN | disclosed |
| US-7001908-B2 | Arylpiperazines having activity at the serotonin 1A receptor | AVERA PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20060009464-A1 | Arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY | 2006-01-12 | — | — | US | disclosed |
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | NOKIA CORPORATION (FI) | 2005-12-22 | — | — | US | disclosed |
| CN-1227241-C | Having 5-hydroxytryptamine 1AReceptor-active arylpiperazines | LILLY CO ELI (US) | 2005-11-16 | — | — | CN | disclosed |
| EP-1100501-A1 | PYRROLIDINE AND PYRROLINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1091741-A1 | AZEPINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2001-04-18 | — | — | EP | disclosed |
| CN-1290258-A | Aryl piperazine compounds with 5-hydroxytryptamine 1A receptor activity | LILLY CO ELI (US) | 2001-04-04 | — | — | CN | disclosed |
| EP-0982304-A1 | Piperidine derivatives having effects on serotonin related systems | ELI LILLY AND COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000000203-A1 | AZEPINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-2000000196-A1 | PYRROLIDINE AND PYRROLINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-2000000198-A1 | PIPERIDINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999031077-A1 | ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR | ELI LILLY AND COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0924205-A1 | Arylpiperazines having activity at the serotonin 1a receptor | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| CN-1097417-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009464-A1 | Arylpiperazines having activity at the serotonin 1A receptor | HTR1A, HTR2A, HTR3A | L3MBTL1 3909/4885TDP1 1281/4885LMNA 4610/4885 |
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | HTR3A, HTR3C, HTR1A | L3MBTL1 3435/4885TDP1 1901/4885LMNA 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.